# Delavirdine – Complete Pharma Product Mastery Guide
---
## 1. Basic Product Identification
* **INN Name:** Delavirdine
* **Brand Name:** Rescriptor
* **Therapeutic Class:** Non-nucleoside reverse transcriptase inhibitor (NNRTI)
* **Indication:** HIV-1 infection (in combination antiretroviral therapy)
* **Route of Administration:** Oral
* **Dosage Form:** Tablets
---
## 2. Therapeutic Knowledge
* Used as part of combination ART (antiretroviral therapy)
* Effective against HIV-1 reverse transcriptase
* Not used as monotherapy due to resistance risk
* Now largely replaced by newer NNRTIs (e.g., efavirenz, nevirapine, rilpivirine)
* Role: historical + limited use in resistant cases
---
## 3. Mechanism of Action (MOA)
* Binds to an allosteric Belgium site on HIV-1 reverse transcriptase
* Causes conformational change → inhibits DNA polymerization
* Non-competitive inhibition
* No activity against HIV-2
* Rapid resistance development via single-point mutations
---
## 4. Pharmacokinetics (ADME)
* **Absorption:** Moderate oral absorption; food may reduce bioavailability
* **Distribution:** Wide tissue distribution; plasma protein binding high
* **Metabolism:** Hepatic via CYP3A4 (major pathway)
* **Elimination:** Primarily fecal, some renal excretion
* **Half-life:** ~5–7 hours
---
## 5. Dosage & Administration
* Typical adult dose: 400 mg three times daily
* Must be taken consistently at same times daily
* Avoid concurrent acid-reducing agents impacting absorption
* Always combined with other antiretrovirals
---
## 6. Formulation Knowledge
* Immediate-release oral tablets
* High-dose frequent dosing formulation challenges
* Excipients designed for rapid dissolution
* Stability-sensitive to moisture and heat
---
## 7. Raw Materials Knowledge
* Delavirdine mesylate API
* Tablet excipients:
* Microcrystalline cellulose
* Lactose
* Povidone
* Magnesium stearate
* Film coating materials for stability and swallowability
---
## 8. Manufacturing Process Knowledge
* API synthesis via multi-step organic synthesis (aryl piperazine derivatives)
* Purification via crystallization and chromatography
* Wet granulation or direct compression
* Blending under controlled humidity
* Compression into tablets
* Film coating for stability and patient compliance
---
## 9. Analytical & QC Knowledge
* HPLC assay for potency
* Impurity profiling (related NNRTI analogs)
* Dissolution testing (critical for bioavailability)
* Content uniformity per USP/EP standards
* Residual solvent analysis (GC)
---
## 10. Regulatory Knowledge
* Approved by FDA (historical approval in late 1990s)
* Now rarely used; many markets discontinued
* Requires strict HIV drug combination labeling
* Subject to stringent antiviral regulatory frameworks
---
## 11. Storage & Stability
* Store below 25°C
* Protect from moisture and light
* Stable in dry conditions
* Shelf-life dependent on packaging integrity
---
## 12. Packaging Knowledge
* HDPE bottles or blister packs
* Moisture barrier packaging essential
* Child-resistant closures in some markets
* Secondary carton with HIV therapy warnings
---
## 13. Safety & Toxicology
* Common: rash, headache, nausea
* Severe: hypersensitivity reactions
* Drug interactions due to CYP3A4 inhibition
* Hepatotoxicity risk (moderate)
* Resistance development is major clinical concern
---
## 14. Market & Commercial Knowledge
* Historically part of early NNRTI market
* Now largely replaced by safer, once-daily regimens
* Limited commercial demand globally
* Mainly used in legacy HIV therapy programs
---
## 15. Intellectual Property (IP)
* Original patents expired
* No major active exclusivity
* Formulation patents also largely obsolete
---
## 16. Environmental & EHS Knowledge
* Antiretroviral residues may persist in wastewater
* Controlled disposal required in pharma manufacturing
* Worker exposure controls needed in API handling
* No major bioaccumulation concerns reported
---
## 17. Export Documentation Knowledge
* Certificate of Analysis (COA)
* GMP compliance documents
* Stability data reports
* Drug regulatory approvals (country-specific)
* Safety Data Sheet (SDS)
---
## 18. Business Development Knowledge
* Low current market opportunity (legacy molecule)
* Potential niche in generic supply chains
* Focus on institutional/government HIV programs
* Mostly replaced in modern ART portfolios
---
## 19. Advanced Technical Knowledge
* Rapid resistance via NNRTI binding pocket mutations (K103N, Y181C)
* Strong CYP3A4 inhibition → major drug-drug interactions
* Requires careful ART regimen design
* Low genetic barrier to resistance compared to newer NNRTIs
---
## 20. AI & Digital Knowledge (Modern Pharma)
* AI models used in HIV resistance prediction
* Digital ART adherence monitoring systems
* Pharmacogenomics integration for NNRTI response prediction
* Drug interaction AI screening tools critical for CYP3A4 inhibitors
---
## 21. Sales Team Product Knowledge Checklist
* Understand why drug is largely obsolete
* Explain NNRTI class clearly
* Know resistance limitations
* Emphasize combination therapy necessity
* Be aware of strong drug interaction profile
---
## 22. Most Important Technical Documents
* Drug Master File (DMF)
* Clinical trial data (hist